[HTML][HTML] Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a …

GJ Feldman, AR Sousa, DA Lipson, L Tombs… - Advances in …, 2017 - Springer
Introduction We report the results of the first direct comparison of the once-daily fixed-dose
long-acting muscarinic antagonist/long-acting β 2 -agonist (LAMA/LABA) combinations …

[HTML][HTML] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled …

…, EM Kerwin, PW Jones, ML Watkins, L Tombs… - Respiratory …, 2019 - Springer
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease …

[HTML][HTML] Measuring disease activity in COPD: is clinically important deterioration the answer?

D Singh, GJ Criner, I Naya, PW Jones, L Tombs… - Respiratory …, 2020 - Springer
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized
clinical management is key to optimizing patient outcomes. Important treatment goals include …

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

D Singh, MR Maleki-Yazdi, L Tombs… - … journal of chronic …, 2016 - Taylor & Francis
Background Minimizing the risk of disease progression and exacerbations is the key goal of
COPD management, as these are well-established indicators of poor COPD prognosis. We …

[HTML][HTML] Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three …

MR Maleki-Yazdi, D Singh, A Anzueto, L Tombs… - Advances in …, 2016 - Springer
Introduction Dual bronchodilator therapy is reserved as a second-line treatment in patients
with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function …

[HTML][HTML] The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing

RD Kempsford, A Oliver, J Bal, L Tombs, D Quinn - Respiratory Medicine, 2013 - Elsevier
Aim To investigate the effect of time of day of dosing (morning or evening) on lung function
following administration of fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg. Methods Double…

[HTML][HTML] Long-term outcomes following first short-term clinically important deterioration in COPD

IP Naya, L Tombs, H Muellerova, C Compton… - Respiratory …, 2018 - Springer
Background Chronic obstructive pulmonary disease (COPD) is characterized by varying
trajectories of decline. Information regarding the prognostic value of preventing short-term …

[HTML][HTML] Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: a pooled post hoc analysis …

R Ray, L Tombs, I Naya, C Compton, DA Lipson… - Pulmonary …, 2019 - Elsevier
Background Elderly patients with chronic obstructive pulmonary disease (COPD) and those
with more severe airway limitation are perceived to experience reduced efficacy from …

[HTML][HTML] Umeclidinium/vilanterol versus tiotropium/olodaterol in maintenance-naïve patients with moderate symptomatic chronic obstructive pulmonary disease: a post …

B Alcázar Navarrete, I Boucot, I Naya, L Tombs… - Pulmonary …, 2018 - Springer
Lee Tombs is a contingent worker on assignment at GSK. Bernardino Alcázar Navarrete
reports personal fees and non-financial support from GSK, grants, personal fees and non-…

How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

…, DA Lipson, C Compton, L Tombs… - Chronic Respiratory …, 2023 - journals.sagepub.com
This review addresses outstanding questions regarding initial pharmacological management
of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves …